 
 
Manual of  
Operations and Procedures  
 
 
Project CLEAR  
Changing Lives by Eradicating Antibiotic Resistance  
 
 
 
Funded by:  
Agency for Healthcare Research and Quality  
 
 
 
 
 
 
 
Principal Investigator: Susan S. Huang, MD, MPH  
 
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
2 
 
 
 Table of Contents  
 
Introduction  ................................ ................................ ................................ ................................ ..............  4 
1. List of Abbreviations and Definition of Terms ................................ ................................ ...............  5 
2. Forms and Bind ers ................................ ................................ ................................ ..........................  7 
2.1 Forms  ................................ ................................ ................................ ................................ ................  7 
2.2 Binders and Files ................................ ................................ ................................ ...............................  8 
2.3 Logs ................................ ................................ ................................ ................................ ...................  8 
3. Key Personnel  ................................ ................................ ................................ ................................ . 8 
4. Participating Centers  ................................ ................................ ................................ .....................  10 
5. Identification Numbers  ................................ ................................ ................................ .................  11 
6. Assessing Eligibility for Recruitment  ................................ ................................ ...........................  11 
7. Inclusion/Exclusion Criteria  ................................ ................................ ................................ .........  14 
8. Informed Consent Process  ................................ ................................ ................................ ............  15 
9. Recruitment/Enrollment Study Visit ................................ ................................ .............................  15 
9.1 Stratification  ................................ ................................ ................................ ................................ .... 15 
9.2 Randomization  ................................ ................................ ................................ ................................  15 
9.3 Participant Education  ................................ ................................ ................................ ......................  16 
9.4 Surveys  ................................ ................................ ................................ ................................ ............  16 
9.5 Body Site  Swabbing  ................................ ................................ ................................ ........................  16 
9.5.1 Swabbing Technique: Nasal  ................................ ................................ ................................ .... 16 
9.5.2 Swabbing Technique: Throat  ................................ ................................ ................................ ... 17 
9.5.3 Swabbing Technique: Inguinal Region and Axilla  ................................ ................................ .. 18 
9.5.4 Swabbing Technique: Open Wounds ................................ ................................ .......................  19 
9.6 Study I ntervention  ................................ ................................ ................................ ...........................  20 
9.7 Scheduling Next Visit  ................................ ................................ ................................ .....................  21 
9.8 Scheduling Bi -Monthly Phone Calls  ................................ ................................ ..............................  22 
9.9 Physician Letters  ................................ ................................ ................................ .............................  22 
9.10 Product Start Date/Study Start Date  ................................ ................................ .............................  22 
10. Central Office Reference Guide  ................................ ................................ ................................ .... 22 
10.1 Daily Tasks  ................................ ................................ ................................ ................................ ... 22 
10.2 Day -Specific Tasks  ................................ ................................ ................................ .......................  23 
10.3 Recurring Tasks  ................................ ................................ ................................ ............................  23 
10.4 Morning Routine  ................................ ................................ ................................ ...........................  23 
10.5 Randomization  ................................ ................................ ................................ ..............................  23 
10.6 Patient Tracking Log ................................ ................................ ................................ .....................  25 
10.7 Scheduling Appointments  ................................ ................................ ................................ .............  25 
10.8 Assigning Appointments  ................................ ................................ ................................ ...............  28 
10.9 Rescheduling and Cancelling Appointments  ................................ ................................ ................  28 
10.10 Disenrolling Patients  ................................ ................................ ................................ ...................  29 
10.11 Adverse Events  ................................ ................................ ................................ ...........................  31 
10.12 Medical Visit Reporting  ................................ ................................ ................................ ..............  31 
10.13 Scanned Consents/Releases  ................................ ................................ ................................ ........  32 
10.14 Creating Consent/Recruitment and Follow -Up Visit Packets  ................................ ....................  33 
10.15 PCP Letters  ................................ ................................ ................................ ................................ . 34 
Project CLEAR MOP Version 1.3 
April 7, 2011 
3 10.16 Exit Survey.................................................................................................................................. 34  
10.17 Reports ………………………………………………………………………………................. 34 
10.18 Shipping ...................................................................................................................................... 35  
10.19 End of Day Laboratory Email ..................................................................................................... 35  
10.20 Study Products ............................................................................................................................ 35  
11.  Follow-Up Participant Tracking and Scheduling .......................................................................... 36  
11.1 Patient Contact .............................................................................................................................. 36  
11.2 Calendars....................................................................................................................................... 37  
11.3 Call Lists ....................................................................................................................................... 37  
11.4 Patient Phone Calls ....................................................................................................................... 37  
11.4.1 Initial Post-Discharge Phone Call .......................................................................................... 37  
11.4.2  Reminder Calls...................................................................................................................... 37  
11.4.3 Product Review/Orientation Calls ......................................................................................... 38  
11.5 Study Helpline .............................................................................................................................. 39  
12.   Bi -Monthly Phone Calls ................................................................................................................ 39  
13.   Follow-up Study Visits .................................................................................................................. 41  
13.1 Participant Education .................................................................................................................... 41  
13.2 Interviews ...................................................................................................................................... 41  
13.3 Adverse Events ............................................................................................................................. 42  
13.4 Medical Events.............................................................................................................................. 42  
13.5 Body Site Swabbing ...................................................................................................................... 42  
13.6 Scheduling Next Visit ................................................................................................................... 42  
13.7 Update Contact Information ......................................................................................................... 42  
13.8 Participant Payments ..................................................................................................................... 43  
13.9 Off Site Follow-Up Visits ............................................................................................................. 44  
13.9.1 Home Visit Procedures .......................................................................................................... 44  
14.   Adverse Event Reporting............................................................................................................... 46  
15.   Obtaining Medical Records ........................................................................................................... 46  
16.   Data Entry ...................................................................................................................................... 46  
17.   Ordering Supplies .......................................................................................................................... 47  
18.  Enrollment Reports ........................................................................................................................ 47  
19.  Specimen Delivery and Order Entry .............................................................................................. 48  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
4 
 
 
 Introduction  
 
This Manual of Operations and P rocedures (MOP) will be used to standardize study procedures 
for the clinical trial, “ Project CLEAR - Changing Lives by Eradicating Antibiotic Re sistance ”. 
Study personnel are to refer to this document when conducting all study procedures . If there are 
further questions or clarification is needed please call/email the Senior Project Coordinator 
Supervisor   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
5 
 
 
 1. List of Abbreviatio ns and Definition of Terms   
 
Abbreviation     
 
Arm of the study:  
E: Education Group 
D: Decolonization  and Education  Group  
 
CHG: Chlorhexidine gluconate. The active antiseptic  ingredient in the Hibiclens body wash and 
Perioguard mouthwash.   
 
ICF: Informed Consent Form. A form that must be signed by subjects documenting their willing 
participation in the study. The ICF explains the objectives, design, risks, and benefits of the 
study  including compensation for participating.  
 
ID: Identification. As in ident ification number for a person or center.  
Study ID numbers associated with e thnicity/location:  
1,000’s and 6,000’s NN: Non-Hispanic /Not long term care facility  
2,000’s HN: Hispanic /Not long term care facility  
3,000’s NL: Non-Hispanic /Long term care facility  
4,000’s HL: Hispanic /Long term care facility  
 
IRB: Institutional Review Board.  A faculty committee charged with reviewing and approving 
the use of human subjects in all research projects to ensure that the safety and welfare of subjects 
are protected.  
 
LTC: Long -term care facility. A facility such as a nursing home, skilled nursing facility, or 
rehabilitation center that subjects may be discharged to, rather than 
house/apartment/condo/townhouse.  
 
MRSA: Methicillin Resistant  Staphylococcus aureus . 
 
MSSA: Methicillin S ensitive  Staphylococcus aureus.  
 
PHI: Protected Health Information.  
 
S. au reus: Staphylococc us aureus . 
 
Specimen Sources:  
NA Nares 
TH Throat  
SK Skin (axilla/groin)  
WD Wound (if applicable for not all patients will have wounds ) 
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
6 
 
 
 UCI: University  of California, Irvine. The primary investigative team site. 
 
UCI-CO: UCI Central Office . The call center to be contacted when randomizing a patient.  
 
VTOC: Vision Tree  Optimal Care.  Web -based database application used for tracking and 
maintaining study d ata for Project CLEAR.  
 
Visit Numbers:  
R0 Recruitment /Enrollment  visit 
V1 Month 1 visit  
V2 Month 3 visit  
V3 Month 6 visit  
V4 Month 9 visit  
 
PT: Participant  
 
 
 
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
7 
 
 
 2. Forms and Binders  
2.1 Forms  
 
All forms for subjects will be available in  English and  Spanish.  
 
            ICF: 
 
1. Adult Informed Consent Form + PHI Authorization  
             
            Questionnaires:  
             
1. Participant Screening Form  
2. Participant Identifier – Enrollment Contact Information  
3. Participant Enrollment Survey  
4. Participant Identifi er – Follow up Contact Information  
5. Participant Follow up Survey (Education)  
6. Participant Follow up Survey  (Decolonization)  
7. Adverse Event Reporting Form  
8. Medical Visit Reporting Form  
9. Trial Exit Survey  
             
            Other:  
             
1. Field Chec klist 
2. Initial Hospital Visit  
3. Consented Patient (Identifier)        
            4. Facilities                                        
            5. Travel                                                 
6. Staff Directory                                     
7. IRB                                               
8. Q & A                                       
9. Study Procedures Checklist  
10. Directions for forms and surveys  
            11. Shipping Specimen Tracking Form  
13. Educational Handout s 
14. Spec imen Labels  
15. Calendar  
16. Missed Appointments Letter 
17. Study Product  
 
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
8 
 
 
 2.2 Binders  and Files  
 
Recruitment  Log File Folder  (Contains: Recruitment, Consent, and Count  Logs for each  
recruitment  center)  
 
Subject File (Contains: ICF, medical information re lease form, c ontact sheet , all questionnaires, 
adverse event forms and medical event forms. Each subject will have o ne binder)  
 
Subject Study Binder  (Contains: study and visit information, MRSA Education and 
Decolonization  
 
Lab Results Binder  (Contains: Co lonization lab results)  
 
2.3 Logs  
 
Central Office Enrollment Log  (List of all randomized and enrolled participants from the various 
participating centers, including the participant’s name, study ID, recruiter, hospital, discharge 
date, and first follow -up visit)  
 
Central Office Lab Count Log  (List of the number of specimen swabs with corresponding Study 
ID numbers collected daily from each recruiter and hospital and sent to the UCI Microbiology 
Lab for processing)  
 
Recruitment Log  (List of eligible MRSA po sitive patients from each participating center —see 
Figure 6.1)  
 
Consent Log  (List of enrolled patients from each individual participating center to be kept at the 
facility —See Figure 6.2 ) 
 
Count Log  (Count of potential participants who enrolled, declined, or were missed at each 
participating center)  
 
3. Key Personnel  
 
Faculty  - UCI: 
Susan Huang – Princip al Investigator  
Steven Park – Co-investigator  
Dan Gillen - Statistician  
 
Study Staff  - UCI: 
Raveena Singh – Sr. Clinical Research Coordinator, Supervisor  
Adrijana Gombosev – Senior Clinical Research Coordinator  
Victor Quan – Senior Clinical Research Coordin ator 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
9 
 
 
 Suzie Hong – Clinical Research Coordinator  
Eric Cui – Assistant Clinical Research Coordinator  
Diane Kim – Assistant Clinical Research Coordinator  
Cam eron Lee – Assistant Clinical Research Coordinator  
Syma Rashid  – Assistant Clinical Research Coordinator  
Courtney Reynolds – MD, PhD candidate  
Chenghua (Mick) Cao – Programmer Analyst  
Jiayi He – Programmer Analyst  
Thomas Tjoa – Programmer Analyst  
Qixin (B ay) Wang – Programmer Analyst  
 
Recruiters  – UCI (Assistant Clinical Research Coordinator) : 
Stephanie Arredondo -Glacet  
Elizabeth Arreola  
Donald Bayley  
Claudia Cervantes  
Heather Clayton  
Nhi Dam  
Tabitha Dutciuc  
Lauren Heim  
Brian Lewis  
Andrea Marcantonio  
Lisa “Angie” McErlain  
Belinda Prado  
Ivonne Turner  
Emily Wawro  
 
Central Office  - UCI (Assistant Clinical Research Coordinator) : 
Nelly Beltran  
Sandra Ibarra  
Maureen Schroeder  
 
 
Central Office Coordinators  (Medical Records Request and Red action) : 
Jennifer Do – Assistant Clinical Research Coordinator  
Phillip Duffy – Assistant Clinical Research Coordinator  
Marlene Estevez – Assistant Clinical Research Coordinator  
Usme Kushbu – Assistant Clinical Research Coordinator  
Jennifer Lequieu – Assistant Clinical Research Coor dinator  
Nicole Mohajer – Assistant Clinical Research Coordinator  
Jennifer Nam – Assistant Clinical Research Coordinator  
Hanna Owens – Assistant Clinical Research Coordinator  
Lauren Akahoshi – Junior Specialist  
Deborah Prunean – Junior Specialist  
Justin Cha ng – Research  Assistant  
Project CLEAR MOP Version 1.3 
April 7, 2011  
10 Institute for Clinical and Translational Science (ICTS): 
Angela Mendoza – Front Office 
Barbara Bodenhoefer – ICTS Nurse 
Diane Capobianco – ICTS Nurse 
Melanie Meton – ICTS Nurse 
UC Irvine Microbiology Lab 
Kaye Evans – Microbiology CLS Supervisor 
Maria Mejia – Microbiology Clinical Laboratory Scientist  
Cynthia Toyoshima – Microbiology Clinical Laboratory Scientist 
Harbor-UCLA:  
Loren Miller – Co-Investigator 
James McKinnell – Co-Investigator 
Michael Bolaris – Co-Investigator 
Samantha Eells – Program Coordinator 
Jenna Alcaron – Study Coordinator 
Isabel Alegria – Study Coordinator  
Ramiro Correa – Study Coordinator 
Nathalia Cressey – Study Coordinator 
Margarita Flores – Study Coordinator 
Ann Nguyen – Study Coordinator 
Katy Precaido – Study Coordinator 
Sean Prendergast – Study Coordinator 
Diana Romero – Study Coordinator  
Aubrianne Rose – Study Coordinator 
Grace Tagudar – Study Coordinator 
Raul Macias-Gil – Lab/Medical Records Review 
Jun Zozobrado – Medical Records Requests 
Ventura County Medical Center :  
Gail Simpson – Co-Investigator 
Stefan Boghossian – Student Intern/Recruiter 
4.Participating Centers
Hospitals: 
Downey Regional Medical Center 
Fountain Valley Regional Hospital 
Harbor-UCLA Medical Center 
Hoag Memorial Hospital Presbyterian  
Little Company of Mary, San Pedro 
Little Company of Mary, Torrance 
Long Beach Memorial Medical Center 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
11 
 
 
 Mission Hospital – Laguna Beach  
Mission Hospital – Mission Viejo  
Orange Coast Memorial Medical Center  
Saddleback Memorial Medical Center – Laguna Hill s 
Saddleback Memorial Medical Center – San Clemente  
St. Jude Medical Center  
St. Mary Medical Center  
Torrance Memorial Medical Center  
UC Irvine Medical Center  
Ventura County Medical Center  
 
Nursing Homes:  
Chapman Care Center  
Country Villa Plaza Convalescen t Center  
Covington Care Center  
Pacific Haven Healthcare  
Regents Point  - Windcrest  
Royale Healthcare Center  
Villa Elena  Healthcare  
 
5. Identification Numbers  
 
Subjects ID numbers are: D or E followed by a four-digit number – NN, HN, HL, NL  
D represents patient s randomized to the decolonization arm  
E represents patients randomized to the education arm  
NN represents patients enrolled in the non -Hispanic, non -long-term care facility stratum  (see 
stratification section 9.1) 
HN represents patients enrolled in the Hi spanic, non -long-term care facility stratum  
HL represents patients enrolled in the Hispanic, long -term care facility stratum  
NL represents patients  enrolled in the non -Hispanic, long -term care facility stratum  
 
Subject ID numbers and Arms (D or E) will be assigned using the next sequential assignment 
within the appropriate strata (NH, HN, HL, NL) per statistician -created randomization file as 
pulled from the randomization block by the UCI Central Office (UCI -CO) 
 
6. Assessing Eligibility for Recruitment  
 
Each medical center may have a slightly different preferred method of identifying MRSA 
positive c ulture s and eligible individual screening. The informatio n below applies in general to 
our participating centers.  
 
 
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
12 
 
 
 Positive MRSA cultures : 
 
Infection prevention a nd control personnel at each site will notify study personnel about the 
eligible inpatients who have a positive MRSA culture (either clinical culture or nasal swab)  by 
providing a line list of positive cultures from the hospital microbiology lab.  
 
Contacti ng Potential Patients:  
 
All patients with a MRSA positive culture will be recorded in the Recruitment Log (Figure 6.1) . 
For all patients with a positive culture that are not enrolled, the reason why the patient is not 
approached or enrolled  will be recorde d according to the following matrix:  
 CODE STATUS MISS Missed opportunity for recruitment, patient not approached for 
recruitment  D1 Declined, minimal to no pitch  D2 Declined, moderate pitch   D3 Declined, full pitch  CONSENT Patient consented   
 
 
Figure 6.1. Recruitment Log  
 
 
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
13 
 
 
 If an eligible patient is still hospitalized , the study coordinator will approach the patient in the 
hospital. Recruiters will leave either a note  or the consent form  in the medical record.  Prior to 
approaching the patient, the recruiter will speak with the patient’s nurse (as the patient may not 
have been told they have MRSA  yet). Once the patient’s nurse approves , the recruiter will then 
speak with the patient  in their room  to determine whether they wish to participate in the s tudy. 
Subjects that agree to participate will be consented at this time . Patients who are unsure  or 
unavailable  will be recorded in the recruitment log by  the coordinator  so that the patient  can be 
approached again  at a later time.  For patients who need ad ditional time to think about the trial, a 
brochure will be left with them with information about the trial.  Trial declinations will also be 
recorded in the Recruitment Log.  
 
When approaching a patient in person , the coordinator  should have all current versions of the 
consent form and PHI form  with them . Study binders  and/or study product will be provided to 
the patient by the coordinator following consent and randomization and will be kept in a 
temporary storage location at the facility until the patient is  ready to be discharged.  
 
Eligible patients  that agree to participate will be consented and recorded in the Consent Log 
(Figure 6.2) . 
 
Eligible patients who were hospitalized , but have now been discharged : If the patient’s treating 
MD during the hospitaliz ation gives permission to contact them, t he study coordinator will call 
the patient at the phone number listed on the hospital chart to approach the patient  and use the 
treating MD’s name to explain how we are reaching out to them . If the eligible patient does not 
answer, the study coordinators will leave a message stating that the patient is eligible for a 
research study. In the message, s tudy coordinators will not mention that the eligible  patient had 
an MRSA infection or colonization. If the patient verb ally agrees to participate, the patient must 
be consented and complete their  baseline visit at the clinic within 30 days  of hospital discharge.  
If the potential patient is unable to come into the clinic, study coordinators may schedule a home 
visit or nurs ing home visit with the patient.  
 
Eligible p atients who are being discharged to a LTC  facility:  The study coordinators will call all 
facilities to make them aware that a patient has enrolled in the study. For LTC facilities not 
already engaged in study pa rticipation, study coordinators will call the facility that the eligible 
patient will be discharged to and assess the willingness of the center to participate. Study 
coordinators will also be available to visit the facility per patien t needs, introduce Pro ject 
CLEAR , and provide instructions on study protocol, e.g., bathing instructions.  
 
Eligible patients who call central office  due to the media campaign : Patients who call the 800 
number because they have seen or heard one of the study advertisements will  speak to study 
coordinators over the phone to determine eligibility. Patients deemed to be meet inclusion 
criteria will have a visit scheduled  for enrollment. Patients must provide documentation of  a 
hospitalization and a MRSA positive culture within 30 d ays of hospitalization in order to be 
enrolled . 
 
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
14 
 
 
 Figure 6.2.  Consent  Log 
 
7. Inclusion/Exclusion Criteria  
 
The Inclusion and Exclusion Criteria Checklist should be reviewed with the patient to determine 
the patient’s eligibility for the study.  
 
Inclusion Criteria : 
 
1) 18 years of age or older  
2) Have a recent hospitalization (within the past 30 days)  
3) Have an MRSA positive culture identified by microbiology laboratory  
4) Able to provide their consent to participate or have a surrogate provide consent  
5) Must be able t o bathe, shower, or have this task performed daily by a caregiver (if 
applicable)  
 
Exclusion Criteri a: 
 
1) The subject is allergic to mupirocin  
2) The subject is allergic to chlorhexidine  
3) Subject is receiving end -of-life hospice measures  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
15 
 
 
 8. Informed  Consent Process  
 
The UCI and LA BioMed institutional Standard Operating Procedures will be utilized as a guide 
for consenting patients. I npatients will be consented in a private or semi -private setting (usually 
their hospital room). Eligible patients  who are contacted ov er the phone will be consented at the 
research clinic , home, or long -term care facility . 
 
If the patient is more comfortable speaking in Spanish, a Spanish -speaking  study coordinator 
should be contacted to approach the patient.  
9. Recruitment/Enrollment  Stud y Visit  
 
The baseline  enrollment  visit must occur either in the hospital before discharge or within 30 days 
of hospital discharge. Items required for the baseline visit include: enrollment survey , contact 
survey, required swabs , study product, and review of the arm-specific toolkit binder.  
9.1 Stratification  
 
Once a patient has been consented , each subject will be classified  into one of four groups:  
  
1) Non-Hispanic  ethnicity and long -term care facility (NL)  
2) Hispanic ethnicity and long -term care facilit y (HL)  
3) Non-Hispanic ethnicity and n on-long-term care facility  (NN)  
4) Hispanic ethnicity and n on-long-term care facility  (HN)  
 
Hispanic ethnicity is based upon self -report (or surrogate report) and long -term care facility 
refers  to the subject being dis charged to a nursing home. Assisted living does not qualify  for long 
term care stratification . The ethnicity and facility information  will be required by the UCI -CO at 
randomization. Study coordinators should collect this information prior to enrollment.  
9.2 Randomization  
 
Subjects will be randomized by calling the UCI  Central Office ( CO) at 949-824-0057 . This  line 
will be answered between the hours of 8:00 and 17:30 . Study coordinators must call CO as soon 
as the subject completes all enrollment and inform ed consent processes . Study coordinators must 
have the subject’s name, gender, ethnicity, and LTC status. The project coordinator at UCI -CO 
will utilize the stratified randomization charts developed by statistician and provide the next 
available assignment  number and arm in chronological order . The study coordinator will inform 
the patient  of their randomization assignment  and proceed to the next step s. For after -hours 
enrollment, please call the Project Coordinator Supervisor . 
 
 
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
16 
 
 
 9.3 Participant Education  
 
Each participant will be provided with an educational binder in his or her preferred language 
(English or Spanish).  Subjects randomized to the Education Arm will receive an education only 
binder. Subjects randomized to the Decolonization Arm will receive the same education material 
as part of the decolonization binder . The study coordinator will review the binder with the 
participant . It is important to note that study  coordinators cannot provide  information  other than 
what is specified in the binder . Stud y coordinators cannot extend specific medical advice to 
anyone. If participants have further questions they should be instructed to contact t heir physician .  
9.4 Surveys  
 
Surveys will be administered  in-person by study coordinators. If the participant  does not know or 
remember the answer, remind the participant to answer as best they can and move on the next 
question. Patients are encouraged to answer all questions and skip questions only when 
necessary . The survey interview should take no more than 20 minu tes.  
9.5 Body Site Swabbing  
 
All participants will be swabbed using a BBLTM CultureSwabTM for S. aureus  colonization at 
four body sites: the bilateral nares , throat, groin and axilla  as a combined swab,  as well as any 
wounds that the patient might have . The body swabs should be sent to the central lab within 24 
hours for processing.  
9.5.1 Swabbing Technique: Nasal  
 
The study coordinator will place a sterile  culture swab  into the anterior nares  of the participant  as 
shown in Figure 9.5.1. 
 
 
Figure  9.5.1: Depicts nasal chambers, nares (pear -shaped apertures) and vestibule.  The culture  
swab is shown inserted through the anterior nares (nostril vestibule) to make contact with nasal 
membrane.  
Project CLEAR MOP Version 1.3 
April 7, 2011  
17 A.Label sample by placing the pre-printed label on the outside of the sleeved device.
B.Use “nares swab” label sticker.
C.Write subject ID number, date/time collected on the label with a permanent marker
(Sharpie or similar).
D.Remove the protective sleeve of the culture swab exposing the shaft and rayon fiber
bud. Only touch the outer hub of the swab without contacting the swab or shaft.
E.Insert swab into sterile transport tube to moisten the swab. If the swab accidentally
touches anything that is non -sterile (e.g. outside of transport tube), discard and begin
again.
F.Tell patient the swab is being moistened with sterile fluid. Tell them you will only go
as far “as someone would put their finger in.”
G.Insert tip of swab 1-2 cm into nares. Insert the sterile culture swab into right anterior
nares into the nostril vestibule toward the apex of the nose to make contact with the
nasal mucous membrane (see Figure 1 )
H.Gently rotate the culture swab for two full turns while in contact with the nasal
membrane.
I.Gently withdraw the culture swab from right nares.
J.With the same culture swab, gently repeat insertion and rotation on the left side
K.Carefully re-sleeve the culture swab.
L.Bury tip of culture swab in gel at bottom of tube.
9.5.2 Swabbing Technique: Throat 
The study coordinator will place a sterile culture swab into throat (tonsil area) of the participant 
as shown in Figure 9.5.2. 
Figure 9.5. 2: Depicts the throat and tonsillar area. The culture swab is shown touching 
(swabbing) the tonsil.   
Project CLEAR MOP Version 1.3 
April 7, 2011  
18 A.Explain to patient what you are about to do.
B.Label sample by placing the pre-printed label on the outside of the sleeved device.
C.Use “throat swab” label sticker.
D.Write subject ID, date/time collected on the label with a permanent marker.
E.Remove the protective sleeve of culture swab exposing the shaft and rayon fiber bud.
F.Only touch the outer hub of the swab without contacting the swab or shaft.
G.Insert swab into transport tube to moisten the swab. If the swab accidentally touches
anything that is non-sterile (e.g. outside of transport tube), discard and begin again.
H.Tell patient the swab is being moistened with sterile fluid.
I.Have patient tilt head back, breathe deeply open mouth wide and have them say
“Ah”. This serves to lift the uvula and aids in reducing the gag reflex.
J.Use tongue depressor to gently depress the tongue, if necessary (consider moistening
the tongue depressor with tap water if the participant gags).
K.Every effort should be made to avoid touching the swabs to the tongue, teeth, roof of
the mo uth or the inside of the cheeks.
L.Carefully but firmly rub the swabs over:
a.Both of the tonsils (or tonsilar crypts if tonsils have been removed).
b. Posterior pharynx (back of throat).
M.Remove swabs carefully from the mouth, again avoid touching the swabs to the
tongue,  teeth, roof of the mouth or the inside of the cheeks.
N.Carefully re-sleeve the culture swab .
O.Bury tip of culture swab in gel at bottom of tube.
9.5.3 Swabbing Technique: Inguinal Region and Axilla 
A.Explain to patient what you are about to do.
B.Label sample by placing the pre-printed label on the outside of the sleeved device.
C.Use “inguinal/axilla swab” label sticker.
D.Write subject ID, date/time collected on the label with a permanent marker.
E.Remove the protective sleeve of culture swab exposing the shaft and rayon fiber bud.
F.Only touch the outer hub of the swab without contacting the swab or shaft.
G.Insert swab into transport tube to moisten the swab. If the swab accidentally touches
anything that is non-sterile (e.g. outside of transport tube), discard and begin again.
H.Tell patient the swab is being moistened with sterile fluid.
I.Put sterile culture swab at bottom Right armpit (See Figure 9.3 ).
J.Swab with upwards motion from bottom to top of R armpit fold.
K.While moving culture swab, upwards, simultaneously rotate swab at least two
complete turns.
L.With same culture swab, repeat technique on the Left armpit fold.
M.With same culture swab, use a similar technique to swab the R groin.
N.With same culture swab, use a similar technique to swab the L groin.
O.Carefully re-sleeve the culture swab.
P.Bury tip of culture swab in gel at bottom of tube.
Project CLEAR MOP Version 1.3 
April 7, 2011  
19 Figure 9.5.3: Depicts the left and right inguinal folds that should be swabbed 
9.5.4 Swabbing Technique: Open Wounds 
Only ZRXQGVWKDWDUHDFFHVVLEOH should be swabbed. Do not disturb wounds that are 
inaccessible (occlusive dressing) or have a wound vac on. 
A.Explain to patient what you are about to do.
B.Label sample by placing the pre-printed label on the outside of the sleeved device.
C.Use “wound swa b” label sticker.
D.Write subject ID, date/time collected on the label with a permanent marker.
E.Remove the protective sleeve of the culture swab exposing the shaft and rayon fiber
bud.
F.Only touch the outer hub of the swab without contacting the swab or shaf t.
G.Insert swab into transport tube to moisten the swab. If the swab accidentally touches
anything that is non-sterile (e.g. outside of transport tube), discard and begin again.
H.Tell patient the swab is being moistened with sterile fluid.
I.Roll the swab ove r the wound, attempt to sample any drainage
J.Carefully re-sleeve the culture swab.
K.Bury tip of culture swab in gel at bottom of tube.

Project CLEAR MOP Version 1.3 
April 7, 2011  
20 9.6 Study Intervention 
Subjects may be given their arm-specific toolkit binder and/or study materials (decolonization 
products) under four different scenarios: 
On the day of enrollment – The study coordinator may provide the toolkit binder to the study 
participant at the time of enrollment once randomized to the respective Education or 
Decolonization arm .
At hospital discharge – In an effort to not lose study materials during a prolonged hospital 
stay, study coordinators may return on the day of discharge to provide the subject with their
toolkit binder and study materials.  Some medical centers may deliver the study materials
(toolkit binder or decolonization products) at discharge via the pharmacy.
After discharge – If a subject is discharged without receiving their toolkit binder or 
decolonization products or if they misplace their study products during their hospital stay the
study material will be mailed or delivered to thei r home.
In clinic/home visit/nursing facility – If a subject is recruited and enrolled outside of a
hospital setting (at home, at the study clinic, or at a nursing home), the study coordinators 
will provide the toolkit binder and study materials at the time and place of enrollment. The 
toolkits will be reviewed in full with each participant at the time of receipt. 
The study toolkit will contain: 
Decolonization Group: 
1) Study product (nasal mupirocin, CHG body wash (Hibiclens) and mouth wash)
2) Calendar cling
3) Copy of the consent form
4) Adverse Event form
5) Medical Visit Reporting form
6) Arm-specific educational binder
7) Appointment reminder card
Education Group: 
1) Copy of the consent form
2) Adverse Event form
3) Medical Visit Reporting form
4) Arm-specific educational binder
5) Appointment reminder card
The recruiter is responsible for assigning the decolonization patients to the Plan A or Plan B 
schedule based upon week of start . The assignment to Plan A or Plan B is based on the first day 
of the initial five day decolonization cycle post discharge. 
Once the patient is informed of the schedule that he or she follow, the study coordinator will 
remind the participant to start bathing for five consecutive days after being discharged from the 
hospital.  The study coordinator will explain to the patient that after five day post discharge 
bathing regimen, they will follow the assigned calendar Plan A or Plan B calendar schedule. The 
Project CLEAR MOP Version 1.3 
April 7, 2011  
21 study coordinator will also remind the participant that UCI CO will call to remind them of the 
decolonization bathing schedule prior to the five-day CHG bathing cycle.  The study coordinator 
will also instruct the participant to add an additional day to the end of their bathing regimen if a 
day is skipped during their assigned bathing cycle.  In the event that the participant miss es two or 
more days of the decolonization bathing cycle, they will have to restart the regimen.     
The patient will b e told that all of the products that they receive are used to reduce bacteria.  The 
study coordinator  will then instruct the study participant on how to use each study product and 
remind that the decolonization products must all be used together: 
Hibiclen s: “This chlorhexidine soap is a body wash/shampoo that needs to be used anytime you 
shower when you are scheduled to be on your five-day regimen. It is intended to substitute your 
body wash, shampoo and facial cleanser. Do not get product into eyes or ear canal. Also, it is 
very important to keep the product on your skin for two minutes while out of the water stream or 
reapply on the skin twice while out of the water stream for a total of two minutes Also, it is very 
important to keep the product on your skin for two minutes while out of the water stream before 
rinsing. The two minutes is approximately the time to soap up twice out of the water stream 
before rinsing .”  The study coordinator will also provide and demonstrate how to use the two-
minute waterproof sand timer. Bactroban Nasal: “ This mupirocin ointment is a prescription nasal 
ointment that needs to be used twice a day, in the morning and in the evening, when you are 
scheduled to be on your five-day regimen cycle.  You will use half a tube for each nostril and 
dispose the empty tube into the container that is provided.”  
PerioGard: “This bottle is a chlorhexidine  oral rinse that needs to be used twice a day, morning 
and evening, when you are scheduled to be on your five-day regimen cycle.  You need to make 
sure you brush your teeth prior to swishing the oral rinse in your mouth for 30 seconds.  Do not 
rinse your mouth with water after using this product. Also, make sure not to eat for at least a half 
an hour after using the oral rinse.”    
The study coordinator will remind the patient that if they have any study-related questions,  they 
may call the toll-free study telephone number where the UCI Central Office will answer any 
questions regarding the study or study products. 
9.7 Scheduling Next Visit 
The study recruiter will make every effort to schedule the one month follow-up visit while 
conducting the enrollment visit if possible. If the participants cannot schedule the follow up visit 
at the time of enrollment, they will be provided with an appointment reminder card with a date 
that the visit should occur (approximately 30 days after discharge). The central office will call 
the participant two weeks prior to the time when the one-month follow -up should occur in order 
to schedule a fixed follow up appointment day, time, and location. See protocol for visit 
schedule. 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
22 
 
 
  
9.8 Scheduling Bi-Monthly Phone Calls  
 
Bi-monthly reminder phone calls should be scheduled the Friday before the start date of the 
intervention week . Central Office staff will reference t he Study Contact Sheet to verify the best 
times to call based on indicated availability   
 
9.9 Physician Letters  
 
Participants are informed that, s hortly after study enrollment,  a notification letter will be sent to 
the participant’s primary physician  as we ll as be placed in their chart  during hospitalization  for 
the inpatient attending physician to see .  The letter informs the physician of their patient’s 
participation Project CLEAR and informs the physician of the study group that their patient has 
been ra ndomized to (i.e. Education or Decolonization). The UCI Central Office will be 
responsible for sending letters to all study participant ’s physicians  on their behal f.  
9.10 Product Start Date/Study Start Date  
 
The product start date vs. trial start date, th ey are the same date, labeled differently  in Vision 
Tree and databases.  Study start date (aka. “Trial entry date” in our analytics dataset for Dan 
Gillen) is termed “product start date” in Vision Tree surveys and was used to capture study start 
date for bo th Decol onization  and Educ ation  subjects.   
 
Admit Date (Hosp) – Admit date of the recruitment hospitalization  
Trial Start Date – Generally the date of discharge or the date of enrollment if enrollment was 
performed post -discharge.  
 
10. Central Office Refe rence Guide  
 
Below is a reference guide describing the daily and weekly tasks of central office coordinators 
for Project CLEAR.  
10.1 Daily Tasks  
x Randomize patients and update tracking log, Recruitment Progress Report will be sent 
out daily  to study investi gators and senior project coordinator  supervisor  
x Create and send out swab  collection  email  
x Call patients for next day’s appointments  
 
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
23 
 
 
 10.2 Day -Specific Tasks  
 
x Monday: Bathing Regimen Cycle Reminder Calls  
x Tuesday: Assign follow -up visits two weeks out (for  example, on week one, schedule 
visits for week three) . Scheduling should occur at least two weeks prior to the visit.  
x Wednesday: Prepare UCI Missed Visit Names report, call patients who have missed 
visits ( in person or for Trial Exit Report) and send out Missed App ointmen t Letter  
Thursday: Based on Trial Exit Repor t, schedule courtesy visits for potential Loss to 
Follow Up patients for coming week  
x Friday: Prepare and send out Trial Exit Report, Prepare Monday Bathing Regimen 
Reminder Call List  
10.3 Recurring Tasks  
 
Note: These do not have to be done on any particula r day of the week, but must be done 
regularly  each week , so as to remain current.  
 
x Create participant consent and follow up visit folders.  
x Scan patient consents and medical r elease forms. Call patients needing exit surveys from 
the UCI List .  
x Create swab bags containing . 
o Specimen Sheets Bio hazard Bags and Lab Requisition  forms (carbon copy 
duplicates)   
o Swabs  
x Create and send out P rimary Care Physician  letters.   
x Maintain supply of compensation forms for recruiters.  
10.4 Morning Routine  
 
1. Obtain  “enrollment  log” & “specimen log” from locked cabinet.  
2. Check voice mailbox to listen to voice messages left from after -hours calls  
3. Locate “Patient Tracking Log” and update with current date  
 
10.5 Randomization  
 
1. Log i n VTOC with username & password. Click on “New P atient” 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
24 
 
 
 
 
2. In VTOC enter the below information. Indicate if PT is Hispani c and if PT is going to a 
nursing home  (Check Yes or No for both)  
 
3. Provide recruiter with new Study ID #   
4. Schedule V1 with recruiter or provide available days/times for patient’s lo cation  
a. For more information, see Scheduling Appointments  (page 6)  
5. Ask the recruiter for the swab count and fill out Lab Count Log (note recruiter may need 
to give swab count to you later in the day)   
6. On paper Enrollment Log, write in recruitment date , recruiter initials , hospital name , 
patient first and last name , and note swab count in margin.  
7. Edit the Contact Sheet in VTOC and select the appropriate recruiter’s name in the 
Recruiter Name pull down. Enter Visit One Date.  
8. Under “initial recruitment” click  new record  to create a new “Participant Scre ening 
Form” – ADD today’s date and  verify  inclusion criteria  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
25 
 
 
 9. Click new record  to create “participant enrollment survey” - ADD today’s date ONLY.  
Note that Today’s Date indicates the Consent Date, not the date da ta entry was done.  
a. If patient was consented POST DISCHARGE, add name of original hospital in 
hospital field. Ex: Hospital: UCI PD (LBM)  
10. Input new participant information into Patient Tracking Log  
11. Text Senior Project Coordinator Supervisor  information : 1-(recruiter (initials) \(hospital 
initials)  
x Example: 1 -IT\UCI 
10.6 Patient Tracking Log  
 
Study patient i nformation is entered into the “tracking log” and applicable information will be 
transferred over to VTOC.  
 
The following information can be found on the “t racking log”  
1. Patient ID & initials - An asterisk (*) will be placed after the ID # for Spanish 
speakers.  
1. Decolonization Plan (differentiated by color: (A-Green or B -Orange)  
2. Discharge date  
3. Recruiter Initials  
4. Notes: used for comments regarding any communic ation with the patient 
(optional)  
IMPORTANT NOTES  are in RED  (Ex: Do NOT call, email pref., Spanish speaking etc).  
5. Initial bathing dates (1st & 5th day) 
6. Date that the  primary care provider  was mailed notification  
7. Consent scanned (Y for Yes)  
8. Clinic visit d ates, time & location  
9. Date exit survey completed  
10. Bathing cycle dates (1stday) 
 
10.7 Scheduling Appointments  
ALL  appointments should be entered in the following locations:   
 
1. VTOC:  
a. Contact Sheet’s Visit Field: Visit One, Visit Two, Visit Three, Visit Four  
b. Communication Log: “HOME VISIT (V#) - Date @ Time; Assigned to [Staff 
Name].” 
 
2. Patient Tracking Log:  
Date, time, location and geographic area (ie: 8/30/13 @12PM Home4)  
  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
26 
 
 
 
3. ENDMRSA calendar – Sample set up:  
 
a. Categorize (Colors listed below) and Invite Attende es 
 
4. Enrollment Log (V1 only)  
 
 ENDMRSA Calendar Color Codes : 
1. Blue= Home, NH, hospital  
2. Red=  ALL cancellations  /no shows  
3. Green = Melanie (Wednesdays) appointments  
4. Light green =Product review /product drop -off/courtesy visit  
5. Light blue = Recruitment visits (post -discharge)  
6. Yellow  = Institute for Clinical and Translational Science (ICTS)  Irvine/Orange  
Visit Scheduling by Area  
1. Institute for Clinical and Translational Science (ICTS)  Nurse Visits  
a. Monday, Friday – ICTS Orange  
b. Tuesday, Thursday – ICTS Irvine  
c. Wednesday – ICTS nurse visits Area 3, 4 and 5 (double check address, must be 
within 15 miles of ICTS Irvine)  
2. Home Visits  
a. As possible, the coordinators are to group Area Visits together and in descending 
order of distance  
i. Geographically distant  visits should be sched uled earlier in the morning if 
possible, so that recruiters can go farthest distance in the morning, and 
work their way back in the afternoon  
3. Home Visits (Spanish)  
a. Schedule when PT is available, but try to group area appointments together (i.e. if 
staff is in Area 4 on Thursday, try to schedule Area 4 visits around that 
appointment)  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
27 
 
 
 ICTS Appointments  
1. Create New Appointment on End MRSA Calendar  
2. Subject: PT ID number (with asterisk if patient is Spanish speaking)  
3. Location: ICTS (Orange or Irvine); Visit Numb er (V1, V2, V3, V4)  
4. Select Time  
5. Message: Patient name and marital status  
6. Invite Attendees: End MRSA, ICTS Scheduling Coordinator and ICT S Nurse.  
7. Categorize as Yellow  
8. Note Appointment in Patient Tracking Log  
  
Home/NH Appointments  
1. Create New Appointment on  End MRSA Calendar  
2. Subject: PT ID number (with asterisk if patient is Spanish speaking)  
3. Location: Home(Area Number) / NH(Area Number); Visit Number (V1, V2, V3, V4)  
4. Select Time  
5. Message: Patient name  
6. Invite Attendees: End MRSA  
a. If scheduling home visit for  Melanie on Wednesday, also invite: ICTS Scheduling 
Coordinator and ICTS Nurse  
7. Categorize as Blue  
8. Note Appointment in Patient Tracking Log  
 
Remote Visits  – Rare. Should only  occur when  patient has moved out of the area (e.g. another 
state), but is still pa rticipating. Relates to  collecting swabs from patients out of the 
coverage area  
1. Call patient before their next visit due date and set up delivery and return of swabs for 
FedEx labels.  
2. Create Visit Packet to overnight to participant  
a. Study Visit Packet Conte nts: 
Decol onizat ion participants receive p roducts for V1 and V2 (V3 and V4 do 
not receive study product) in addition to items listed below  
i. Visit Surve y Questionnaire  with a “CONFIDENTIAL” envelope (this will 
need to be picked up from UCIMC Micro Lab)  
ii. Swab bag (label the stickers and  study paperwork  with Visit #, Study ID, 
swab collection site (Na, Thr, Sk, Wd) and date that the patient is to 
complete  swabbing  
b. Compensation  
i. Subject Compensation Form  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
28 
 
 
 x Fill out the following:  Date Paid, Cash (with corresponding visit 
amount) , Amount Paid, Home Visit CASH Sign Out (your 
signature) and PT signs “Paid To” column – Overnight to PT  
 
ii. Compensation ( wait until signed compensation is received)  
x $ in small envelope labeled and sealed  
“VISIT [#] COMPENSATION  
FOR: __________________  
 
iii. FedEx Package  
 
10.8 Assigning Appointments  
 
x There will be one primary study coordinator for home visits  
o Try to make sure that there is as little duplication of area assignments as possible 
(if one st udy coordinator is conducting an appointment in Area 4, ensure that a 
second study coordinator does not have to drive there as well).  
 Note: study coordinators will be assigned to area visits that are closest to 
their geographical location (home)  
x All Spanish appointments will be assigned to a  Spanish speaking study  coordinator. 
Senior Project Coordinator Supervisor will also receive an invitation as an FYI)  
x Post-discharge R0 Enrollment Visit appointments  should be scheduled according to the 
regular home visit schedule and study coordinators assigned to the closest g eographical 
area  
Note: R0 Enrollment Visit  appointments will t ypically require a full hour and should be 
scheduled accordingly and take driving time into consideration as well  
10.9 Rescheduling and Cancelling Appointments  
 
1. If an appointmen t is CANCELLED - change category to RED, indicate CANCELLED 
next to Study ID, add today’s date w/ notes in comments section.  
2. If an appointment is RESCHEDULED -keep same color category (unless it needs to be 
changed), update date and time, add current date and notes in com ments section, and 
resend  a new appointment invitation . 
i. Note: Keep original appointment on the calendar & create a new calendar 
appointment if study coordinator  drove to destination but  the appointment 
had to be rescheduled  for any reasons .  
3. Inform ICTS Sc heduling Coordinator  of any ICTS cancellations or reschedules by editing 
existing calendar invite.  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
29 
 
 
 a. If it is a last minute cancellation or reschedule, make sure to also call the ICTS 
Appointment Center . 
4. Save new date & time to: tracking log, contact sheet & comm unication  log (VTOC).  
10.10 Disenrolling Patients  
 
Patients are considered to be an “early” exit/disenrollment if they exit the study due to death, 
active disenrollment, or confirmed lost to follow up.   
 
Active Disenrollment :  
1. If a patient expresse s that they cannot participate in the study, the study coordinators will 
document reasons for withdrawing partici pation, attempt to address concerns and 
encourage continued participation , if possible.  During the disenrollment interview, the 
coordinator is  to attempt to gather  outcomes data from the patient ( they will ask if the  
participant has been re -hospitalized or ha s visited a clinic for a possible infection).  
2. Fill out a Medical Visit  Reporting Form  if applicable   
3. If they are adamant about dropping, n otify the Senior Project Coordinator Supervisor via 
email and cc: the patient’s recruiter and End MRSA  email account .  
a. In the email, the participant’s ID # will be included in the subject line and a brief 
summary of the situation  will be descr ibed in the b ody of the email.  
4. A summary of the disenrollment even t will also be recorded in the VTOC 
Communication Log.  
5. After the Senior Project Coordinator Supervisor has followed up with patient, the patient 
will be added to the Trial Exit Report.  
6. The patient will also be added to the “Physician Follow Up ” Spreadsheet (Non -
Participant List tab)  for follow -up discussions and documented decisions regarding trial 
exit. 
7. The VTOC Enrollment survey  will also be updated   
a. Complete Change of Enrollment Status section  
i. Click YES  
ii. Enter Date Disenrolled  
iii. Set Reason Disenrolled to DECLINE  
iv. Select the appropriate value for Reason Declined and give description 
under Notes.  
1. IMPORTANT: If no known outcome data is obtained during this 
time, use last date patient provided outcome data (Ex: RO, V1).  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
30 
 
 
 
 
8. Update Patient Tracking Log  
a. Highlight patient entry in red  
b. Note “Active disenrollment” and “Supervisor notified” in comments section  
Death :   
1. If study staff is informed that a patient has expired , request information on the exact date 
of death, cause of death and if the  patient expired at home/hospital.   
a. Study staff will attempt to gather outcome information by inquiring whether the 
patient was re -hospitalized or had a medical visit for an infection prior to death.  
b. A Medical Visit Reporti ng Form  will also be completed.   
2. Update the Physician Follow Up spreadsheet.   
3. Patient will be added to the Trial Exit Report  
4.  The VTOC Enrollment survey  will be updated .  
a. Fill out Change of Enrollment Status section.   
b. Enter Date of Death  
c. Set Reason Dise nrolled to “Death”  
d. Add description under Notes for disenrolling.  
5. Patient Tracking Log  will be updated.  
a. Highlight patient entry in red  
b. Note “Patient deceased” and date of death in comments section  
Confirmed Lost to Follow Up :   
1. A patient will be considered  confirmed lost to follow up when study staff are unable to 
contact patient for three or more months.  
a. Contact attempts should include phone calls (to patient, alternate and emergency 
contacts), courtesy visit attempts, and engaging the original patient recruiter for 
new phone number/checking for readmission.  
Cent ral Office will:   
2. Update the Physician Follow Up spreadsheet.   
3. Add patient to the Trial Exit Report  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
31 
 
 
 4. Update VTOC Enrollment Survey  
a. Fill out Change of Enrollment Status section.   
b. Set Reason Disenr olled to “Lost to Follow Up”.   
c. Date Disenrolled is set to date of last known outcomes.  
d. Add description under Notes for disenrolling.  
5. Update Patient Tracking Log  
a. Highlight patient entry in red  
b. Note “Active disenrollment” and “Supervisor notified” in comm ents section  
10.11 Adverse Events  
 
After receiving notification from a recruiter or patient via telephone/email  that a study 
participant has experienced an adverse event, central office will :  
1. Page study physicians  using a secured intranet portal   
2. A study  physician will speak to patient s who are reporting a study related  AE.  
3. Fill out Adverse Event Form on VTOC  
a. Beneath “Unscheduled Events”, click “New Record” next to “Adverse Event 
Reporting Form”.  
b. Fill out all information as possible according to the fo rm. 
4. Wait for the study physician’s follow -up email & transcribe the assessments into the 
Physician Follow -Up spreadsheet:  
a. Fill in  information under tab marked “Adverse Events”  
b. Save with current date.  
5. The patient will be contacted  by a study member daily u ntil resolved  (this will include 
any deemed non study related  events ) and update s will be entered into  VTOC  and 
Physician Follow -Up spreadsheet.  
10.12 Medical Visit Reporting  
 
If a patient indicates they have been to a hospital/NH/rehab center for any rea son OR ha ve 
visited the ER or outpatient clinic due to an infection , a Medical Visit Report ing Form  must be 
completed and entered into VTOC.  
1. To fill o ut Medical Visit Reporting  Form on VTOC  
a. Under “Unscheduled Events”, click “New Record” next to “Medical V isit 
Reporting Form”  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
32 
 
 
 b. Fill out all information as possible according to the 
form
 
 
10.13 Scanned Consents/Releases  
 
All consent forms and HIPPA Authorization forms are to be filed electronically as well as within 
paper files as well. In order to ensure all  consent forms are properl y scanned, central office will:  
1. Review Patient Tracking Log to see what consents need to be  scanned.  
a. “Y” for Yes will be placed in the corresponding cell to indicate that the consent 
signature p age/surrogate signature form has be en scanned.  
2. Locate files in Central Office Cabinets  
3. Create new folder w/ Study ID in the scanned consents folder  
4. Go to “Xerox Scans” to find the newly scanned consents and rename each signature 
document .  
a. Ex: D -2222 -NL Consent or D -2222 -NL Surrogate  or D-2222 -NL Release    
5. Ensure consent is appropriately completed . If not, the study recruiter must be contacted 
immediately  
6. Move renamed documents into appropriate folders  
7. Open corresponding Consent without Signature Page  
8. Append signature page  
a. Go to Document Æ Insert Pages Æ From File  
b. Select Patient’s Consent Page (i.e. D -2222 -NL) and insert at appropriate place  
i. Double check after insertion that page numbers and consent versions 
match up  
c. Save Document as Consent in the Scanned Consents folder (i.e. as D -2222 -NL) 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
33 
 
 
 i. You will be asked if you are sure you want to replace the current 
document  
ii. Click Yes  
10.14 Creating Consent/Recruitment and Follow -Up Visit Packets  
 
Consent/Recruitment Packets:  
*Consent Packets should all have the following:  
1. Screening Form  
2. Consent Packet (Corresponding to hospital)  
a. Consent Packets ( UCI) – to be used for UCI, Hoag or any post discharge 
recruitment.   
b. Consent Packets (UCI) Spanish  
c. Consent Packets ( Mission ) 
d. Consent Packets ( Memorial ) 
e. Consent Packets ( Fountain Valley ) 
3. Extra signature page (exempt Mission & Memorial) – Spanish Signature Page  
4. HIPPA (UCI)  – Spanish HIPAA UCI  
5. HIPAA (Project CLEAR )- Spanish HIPAA Project Clear   
6. HIPAA (Memorial)  – only for Memorial Consents  
7. Contact Sheet  – Spanish Contact Sheet  
8. Enrollment Survey  – Spanish Enrollment Survey   
9. Medical Release Forms  (2) – Spanish Medical Release Forms  (2) 
10. Consent Checklist  – Spanish Consent Checklist  
11. Dear Dr. Letter  – to be placed in the patient chart for the attending physicians  
 
Follow Up Visit Packets:  
1. Deco lonization  FU (English & Spanish)  
a. Envelope for Cash  
b. Cash Payment Form   
c. Decolonization Follow -Up Survey  (Spanish ) 
d. 2 Medical Visit Reporting Form s (Spanish ) 
e. 2 Adverse Event Form s (Spanish ) 
f. 2 Medical Visit Worksheet s (Spanish ) 
2. Education FU (English & Spanish)  
a. Envelope for Cash  
b. Cash Payment Form   
c. 2 Education Follow -Up Survey s (Spanish ) 
d. 2 Medical Visit Report Form s (Spanish ) 
e. 2 Medical Visit Worksheet s (Spanish ) 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
34 
 
 
  
10.15 PCP Letters  
Primary Care Physician  letters are generated for all patients . 
10.16 Exit Survey  
 
The Trial Exit Survey should be conducted approximately one year after enrolled  (i.e. 365 days 
after d ischarge or consent d ate, which ever is greater).   
In order to complete the trial exit survey, central office will:  
1. Check the Patient Tracking Log for Patients who are to complete their exit survey based on 
the above criteria.  
2. Call patient and ask if he or she has a few minutes  to complete a quick exit survey over the 
phone.  
3. If so, Click on “New Record” underneath Exit Survey on VTOC.  
 
4. Complete the questions listed within the trial exit survey  
a. Fill out Medical Visit Form on VTOC if necessary (VTOC will prompt).  
5. Thank the patien t for participating in the trial. 
6. Inquire if patient would be interested in future studies. Note their response in Communication 
Log, along with completion status of survey.  
7. If a patient request s their lab results, inform the participant that the Senior Pr oject 
Coordinator Supervisor  will follow up within a week.  
a. Each week, send Senior Project Coordinator  Supervisor a list of patients who have 
requested their lab results.  
10.17 Reports  
 
Central Office will distribute a study p rogress report  to Senior Projec t Coordinator Supervisor  
and principal investigator daily. This progress report with include updates to the recruitment 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
35 
 
 
 
numbers, dis -enrolled participants, follow up visits and status, as well as any other pertinent 
information involving the progress of th e trial.  
 
Additionally, quarterly reports will be sent to each participating facility’s study champion 
and infection prevention team to inform them of the recruitment progress in the trial and 
at their site.  
10.18 Shipping  
 
There will be situations where c entral office will assist with specimen s that are shipped to UCI 
Medical Center for processing (from out of area visits o r enrollment), as well as with the 
shipment of deidentified MRSA isolates that are sent to Rush University for resistance testing . 
10.19 End of Day Laboratory Email  
 
A summary email will be sent to the UCI microbiology lab daily to confirm the number of 
cultures that are to be received.  A sample email is included below:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10.20 Study Products  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
36 
 
 
  
Recruitment visit bags include:  
 
 Visit Type Hibiclens Bactroban Periogard Sponges Container/Timer Lotion Pump Recruitment 1 3 1 3 1 1 1 V1 1 4 1 4 n/a n/a n/a V2 2 6 2 6 n/a n/a 1 V3 n/a n/a n/a n/a n/a n/a n/a V4 n/a n/a n/a n/a n/a n/a n/a  
11. Follow -Up Participant Tra cking and Scheduling  
 
Study personnel are responsible for keep ing track of scheduled visits  and updating contact 
information  to ensure t hat subjects  remain in the study. It is of the utmost importance that 
participant  data are documented and kept well organized so as to avoid loss of information.  
 
Harbor UCLA recruiters are responsible for following up with appointments for participants 
recruited from their facilities.  UCI Central Office is responsible for following up on 
appointments for all other partic ipants.   
 
UCI-based Enrollees  
Visit 1 appointments are scheduled by recruiters during the initial enrollment visit. Subsequent 
study visits (V2 – V4) are scheduled with the patient by the ICTS clinic nurse or 
coordinator/recruiter completing the follow u p visits. UCI recruiters schedule appointments by 
calling the ICTS appointment line (714) 456 -2307  and then notifying UCI Central Office.  ICTS 
nurses will record subsequent appointments into VTOC and email UCI Central Office on 
scheduled clinic visit date s, times and locations. UCI Central Office records all scheduled 
appointment into the Patient Tracking Log, ICTS appointment log or Recruiter appointment log, 
calendar, and ensures that the VTOC database is updated accordingly. Each Friday, UCI Central 
Office sends the ICTS nursing staff the appointment log to ensure that there are no discrepancies 
between the ICTS calendar and UCI Central Office records.  
11.1 Patient Contact  
 
Contact information  sheets  for subjects  will be kept in a locked  cabinet when not  in use. Contact 
information should be entered into VTOC within 24 hours of recruitment.  All  communication 
with a patient should be logged in the VTOC Communication Log. The date, time , mode, staff, 
urgency, category, and status in the Communication Log s hould be filled out along with the 
description of the communication with the patient.  
 
UCI Central Office is responsible for tracking all important study events for UCI -based enrollees 
in the Patient Tracking Log excel spreadsheet and VTOC Communication L og.  The log includes 
the patient Study ID, patient initials, recruiter initials, discharge date, decolonization plan (A/B), 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
37 
 
 
 clinic visit dates, decolonization regimen cycle start and end dates, and reminder phone call 
dates.   
11.2 Calendars  
 
Subject sche duling will be managed through the study website calendar. Once a patient is 
enrolled, study coordinators are responsible for updating the calendar within 72 hours.  
11.3 Call Lists  
 
UCI uses the Patient Tracking Log to track which patients must be called f or initial bathing, 
regular start bathing cycles, and appointment reminder calls.  UCLA uses a similar tracking log 
to determine phone calls that must be made to patients.  It is anticipated that VTOC will soon 
have a function to facilitate listing events such as bathing, appointments, and follow up that must 
be made on a given date or time period across all subjects in the VTOC database.  Based on the 
event type and/or date enter as parameters, VTOC will list all patients requiring phone calls or 
additiona l follow back.  
11.4 Patient  Phone Calls  
 
Patient phone calls are made by the UCI Central Office to the Decolonization patients up to five 
times per month. Patients assigned to the Decolonization group will be called after hospital 
discharge or on the date the patient indicated they would be able to start using the study products, 
the first and last day of their initial bathing cycle, the first day of their subsequent bathing cycles 
and the day prior to their scheduled clinic/home visits.  
Patient phone call s are made by the UCI Central Office to the Education patients up to two times 
per month. Patients assigned to the Education group may be called after hospital discharge, on 
any day of the month to follow -up on any questions they may have regarding the edu cational 
materials and/or the study in general. Education patients will also be called the day prior to their 
scheduled clinic/home visits.  
11.4.1 Initial Post -Discharge Phone Call  
 
The UCI Central Office is responsible for calling each patient the next bu siness day after hospital 
discharge.  Patients assigned to the decolonization arm should be instructed to immediately begin 
their five day decolonization regimen. UCI Central Office will also answer any questions the 
patients might have about using the dec olonization products or any general study questions. The 
toolkit binder should have been reviewed in full with each participant at the time of enrollment, 
so focused questions should be answered or a courtesy visit can be schedule d for additional 
support a s requested by the participant.  
 
Patients assigned to the Education Arm may also be called post -discharge, at the discretion of the 
recruiter, to answer any further questions about the study educational materials  or any general 
study questions . The toolkit  binder should have been reviewed in full with each participant at the 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
38 
 
 
 time of enrollment, so focused questions should be answered or a courtesy visit can be scheduled 
for additional support as requested by the participant.  
 
11.4.2 Reminder  Calls  
 
Reminder  phone calls for all study visits should be made 48 to 24 hours before the visit will 
occur. The outcome of reminder calls must be documented in the patient contact database. A 
message will be left if the subject does not answer. If a message cannot be lef t, coordinators will 
call the subject three times throughout the day. All phone call attempts will be documented in the 
patient contact database.  Subjects will be called on 3 different days to attempt to reschedule the 
visit.  
 
Bathing:  Initial bathing (sta rt & stop calls) - After PT has been discharged, each person 
(decolonization & education) is called to follow -up on the products given (binder/soaps 
& medicines), reinforce product start date adherence, answer general study questions and 
remind/ schedule V 1.  
Monday calls - All decolonization PTs are called on Mondays depending on Plan (A or B), see 
laminated calendar for assignment.  
 
Decolonization patients have five day bathing cycles (Monday – Friday) twice a month .  The 
dates of those cycles are determi ned on whether the patient is assigned to Plan A or Plan B.   
11.4.3 Product Review/Orientation Calls  
 
All patients that require product review/orientation are listed on the Product Review Spreadsheet  
from which central office study staff can reference for  follow -up calls or visits.  
. 
General script for contacting study participants : 
 
Phone Call:  
Hello, this is ___________ from Project CLEAR, may I speak with ________________?  
Great! I was just calling to see if you had any questions about the trial, the ed ucational 
materials, or the decolonization products. I also wanted to offer to have someone drop by 
to go over the products and educational materials if you needed a refresher.  
Yes: Ok, no problem at all. We are in your area…  
No: Ok that’s great! If you h ave any questions, please feel free to call us and otherwise, 
we will see you on __date/time @ location__ for your first follow up visit! (Confirm 
address if home visit)  
 
 
Voicemail:  
Hello, this message is for ____________. My name is _________ and I am ca lling from 
Project CLEAR. I was calling to see if you had any questions about the educational 
materials or the products, and if you needed a refresher on how to use the products, I will 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
39 
 
 
 be in the area this Friday afternoon from 12 -4. Please feel free to gi ve us a call at 855-
END -MRSA or 855 -363-6772.   
 
1. If the patients are education patients, the script will be  modified to not reference the 
decolonization products.  
2. If the patients are nursing home patients, the nursing home will be contacted by senior 
study  staff for collaboration.  
11.5 Study Helpline  
 
A 1-800 helpline desk number plus a n emergency pager number ( the Senior Project Coordinator 
Supervisor ) will be provided to the subjects . This 24 -hour helpline is intended for Adverse Event  
reporting , urgent Medical  Visit Reporting  or any other urgent questions or concerns from study 
participants.   
 
  
12. Bi-Monthly Phone Calls  
 
Bi-monthly courtesy phone calls, intended to remind subjects of the upcoming study 
intervention , will occur the Friday prior to the 1st and 3rd or 2nd and 4th Monday of each month , 
depending on Plan A or Plan B . An additional call will be made on the Monday of a 
decolonization week to initiate the regimen and the Friday of a decolonization week to stop the 
intervention. A voicemail  will be left if t he subject does not answer. If voicemail is not available , 
coordinators will make three additional call attempts that day . All phone call attempts will be 
documented in the patient contact database.  
 
Coordinators will call subjects who have be en randomized to the intervention arm (serial 
decolonization) to:  
x Remind them to begin the study intervention  
x Inquire about adverse events  
x Inquire about medical issues  
x Re-educate patients on how to use the study products  
x Answer any questions the subject ma y have  
 
 
Start Regimen Script:    
“Hello, may I please speak to Mr. /Ms. <patient’s last name>?  My name is <caller’s name> 
and I am calling from the Project CLEAR MRSA study to remind you to begin your five day 
Hibiclens bathing, nose ointment, and mouthwa sh regimen today.  Will you be able to start 
today?”   
 
(Patient says yes): “Great, the products work best against MRSA when you use all 3 
together for all five days and don’t miss any doses”.  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
40 
 
 
  
(Patient says no) – Find out why and if they can start the nex t day.  If there is a delay in 
starting the regimen, be sure to have them start up as soon as possible and continue for 
five consecutive days.  
 
“One last question for the study, we always ask that you let us know if you have been 
hospitalized for any reas on or have had a clinic visit for a possible infection.  Do you have 
either of those to report?  Any other questions I can answer?  Call us anytime toll free at 
855-END -MRSA. ” 
 
If the patient does not answer the call, it is acceptable to leave a message if  the patient has 
indicated that messages may be left.  Check the patient’s contact sheet to see if they answered 
yes or no to “Is it okay to leave messages on this number?”  Use the script below when leaving a 
message.  
 
Start Regimen Message Script:   
“Hell o Mr./Ms. <patient’s last name>, I am calling from the Project CLEAR MRSA study to 
remind you to begin your five day Hibiclens bathing, nose ointment, and mouthwash regimen 
today.  We also wanted to remind you to please let us know if you have been hospita lized for 
any reason or have had a clinic visit for a possible infection.  We can be reached anytime toll 
free at 855-END_MRSA .” 
 
Fill out a Medical Visit Reporting Form if a patient reports any hospitalizations for any reason or 
visits a clinic or doctor for a possible infection.  Fill out an Adverse Event Reporting Form if the 
patient reports any adverse effects.  See S ection 14  for more information on reporting adverse 
events  
 
Add-on Lines to calls, rotating:   
Scripted add -on to use when making calls/lea ving messages  (pick one or more & rotate):  
1. Bactro ban – Since MRSA’s main home is  in the nose, be sure to use the nose ointment in 
the morning and at night during your 5 -day bathing cycles to stop it from living in your 
nose.   
2. Hibiclens – Each time you bath e during your 5 -day cycle, it is important to l ather with 
the water off and  leave the Hibiclens on your skin for 2 full minutes before rinsing off.   It 
is also very important that you not use any other soaps, shampoos or lotions during your 
5-day bathing c ycles since some of them make Hibiclens stop working.  
3. Periogard – Sometimes MRSA will also live in the throat. Be sure to use the special 
mouthwash (Periogard) in the morning and at night  during your 5 -day cycles. Swish for 
30 seconds and don’t rinse with water immediately after using.  
4. Your best chance of getting rid of MRSA is when you use all three products together. Let 
us know if you need more before your next visit with us .   
 
The above statements can be followed with “Do you have any questions ?” 
 
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
41 
 
 
 Additional Info:  
x ONLY stop bathing calls (prior to V3) when a patient requests not to be called.  
- Send email if possible to these patients.  
x Any changes to PT’s regimen Plan or to call list should be noted in Communication Log 
on VTOC and Patient Tracking Log.   
 
13. Follow -up Study Visits  
 
The UCI ICTS clinic hours for Project CLEAR are Mondays and Wednesday 8am -5pm at the 
UCI Medical Center in Orange, and Tuesdays and Thursdays 8am -5pm at the ICTS Clinic on the 
UC Irvine campus in Irvine. Weekends are availabl e upon request.  
 
The Harbor -UCLA CTRC Outpatient Clinic is open 7:30am to 4pm Monday through Friday. 
Subjects can be seen outside of these hours at the Inpatient CTRC Monday through Friday. 
Saturday follow -up visits can be arranged with prior notice.  
 
Hom e and/or nursing home visits will occur when a subject is unable to come into the clinic for a 
study visit. Subjects who move or do not wish to have in -person visits may have their visit 
conducted over the telephone.  
 
The follow -up visits occur at 1, 3, 6 , and 9 months after the baseline visit.  
 
Subjects will undergo the same body swabs as occur at the baseline visit and they will be 
administered a follow -up survey. Subjects will be compensat ed as outlined in Section 1 3.8. 
13.1 Participant Education  
 
If the participants request  an additional patient education binder , it will be provided  in their 
preferred language (English or Spanish).  
 
Subjects will be provided reminder educational handouts specific to each follow -up visit. Study 
coordinators will review these handouts and any other information the subject would like to go 
over.  
13.2 Interviews  
 
The surveys will be completed  in-person by study personnel . If the participant does not know or 
remember the answer, remind the participant to answer as best they can and move on the next 
question. The interview should take no more than 20 minutes.  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
42 
 
 
  
13.3 Adverse Events  
 
Adverse events will be recorded at the time the  study coordinator becomes aware  of the event. 
Study coordinators can be made aware of an adverse eve nt in four  ways:  
1. The subject reports an event over the phone on a Bi -Monthly Call  
2. The subject reports an event over the phone on a Reminder Call  
3. The subject calls the 1 -800 helpline number or page s the Senior Project Coordinator  
Superviso r 
4. The subject repo rts an event at a follow -up visit  
 
All adverse events will be followed until resolved, unless t he subject exits the study  and requests 
no contact.  
 
Serious Adverse Events will be handled as described in the protocol Section 14. 
13.4 Medical Events  
 
If a pa tient affirms that they have been hospitalized or had an outpatient visit associated with a 
suspected MRSA infection on a phone call or follow -up visit, study  coordinators will fill out a 
Medical Event Form and an Adverse Event Form with the subject. Patie nt will be asked to obtain 
recor ds of their visit if easy to do so. Study coordinators will also contact the medical center the 
patient was seen at to request the medical records .  
13.5 Body Site Swabbing  
 
The same four body sites (nares, throat, groin/axi lla, and wounds) will be swabbed at the follow -
up visits. Refer to Section 9.5 for more informat ion on how to swab body sites.  
13.6 Scheduling Next Visit  
 
Attempt to schedule the 1 month follow -up visit during the baseline visit whenever possible. If 
the participants cannot schedule the next visit, give them an appointment reminder card with the 
date on which the visit should occur. Two weeks before the 1 month follow -up visit, call the 
subject  to schedule the appointment. The next study visit should alway s be scheduled at the 
current study visit; for example, the 6 -month visit should be scheduled at the 3 -month visit.  
13.7 Update Contact Information  
 
Study coordinators must ask the subject to update their  contact information  prior to the end of a ll 
study v isits. This includes:  
 
x Phone number  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
43 
 
 
 x Address  
x Emergency contact  
13.8 Participant Payments  
 
The participants will be compensated with cash at the  completion of each follow -up visit.  
x $25 for the 1 month follow -up visit  
x $30 for the 3 month follow -up visit  
x $35 for the 6 month follow -up visit  
x $50 for the 9 month follow -up visit  
x $140 for the whole study  
 
Fill out the Certification of Payment (see Figure 1 3.8) with the lead study coordinator’s name, 
date, study IRB number, and the participant’s name. Have the part icipant sign the receipt. At this 
time they will be given the cash.  
 
Figure 1 3.8: Certification of Payment to Anonymous Persons  – ICTS Irvine  
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
44 
 
 
  
 
13.9 Off Site Follow -Up Visits  
 
If the subject is unable to come in for the follo w-up visit due to hospitaliz ation or residence in a 
nursing home,  study coordinators will complete the study visit at the medical center , nursing 
home , or patient’s home , wherever the subject is currently residing.  
 
13.9.1 Home Visit Procedures  
 
The following items are needed prior t o the home visit:  
• Project Clear Lab Coat (See VTOC for notes on patient preference for or against a lab 
coat)  
• UCI Badge  
• Gloves (Wear while swabbing patient)  
• Anti-Bacterial gel/wipes  
• Prepared Swabs (4 s terile s wabs per bag with labels, carbon copy white/yel low form, and 
1 white form)  
• Pen 
• Visit Compensation Amount (V1 -$25, V2 -$30, V3 -$35, V4 -$50) with small manila 
envelope  
• “Certification of Payment to Anonymous Person – ICTS Irvine” form (see Figure 13.8).  
• Patients Name, ID Number, and Contact Details (addres s & directions)  
• New Binder Sections : 
 V1: N/A  
 V2: “MRSA & Pets”  
 V2: General binder r eminder  
 V3: V3 General binder reminder (Decol ONLY)  
 V4; N/A  
• Calendar and area chart to book next visit (Month 1, 3, 6, 9)  
• Staffed ICTS and Orange Clinic Visit Dates (Mon & Fri –  Orange; Tues & Thurs – ICTS 
Irvine)   
• Business card to write down next visit date and time for patient  
• Pocket calendar note book or scrap paper to write next visit date to bring back to Central 
Office  
• Trash Bag (for gloves, swab packaging, and to pl ace empty Bactroban containers in after 
counting if Decolonization patient)  
  
If Patient is in Education Group:  
1. “Participant Follow -up Survey Education”  
2. “Medical Visit Reporting Form” x 2 (Same form used for Decolonization patient)  
Project CLEAR MOP Version 1.3  
April 7 , 2011  
45 
 
 
 3. “Medical Visit Workshee t” x2 
 
If Patient is in Decolonization Group:  
1. “Participant Follow -up Survey Decolonization”  
2. “Adverse Event Reporting Form” x 2  
3. “Medical Visit Reporting Form” x 2 (Same form used for Education patient)  
4. “Medical Visit Worksheet” x2  
5. Prepackaged CHG Complian ce Test Swabs (2 swabs per package with form)  
6. Replenishment Products  
 
 V1 Bags (1 month after enrollment)    
• 1 Project Clear Canvas Bag (Containing below items)  
• 4 Sponges  
• 1 Hibiclens (1 bottle should last 2 months, ask how much used prior to visit)  
• 4 Bactroban  
• 1 Periogard  
• 1 Pump (If needed)  
 
V2 Bags (3 months after enrollment)  
• 2 x Project Clear Paper Bags  
• 6 Sponges  
• 2 Hibiclens (1 bottle should last 2 months, ask how much used prior to visit)  
• 6 Bactroban  
• 2 Periogard  
• 1 Pump (If needed)  
 
Check Vision Tree (VTOC) for:  
• Specific patient notes i.e. needs translator for patient or caregiv er, non -communicative 
patients so look for the main contact, ability to be swabbed, unusual home conditions  
• Notes on previous medical visits already recorde d in VTOC so not duplicated  
 
Post Visit  
• In VTOC , briefly report on visit in “Communication Log” (Ex: Home Visit (V1), 
completed.)  
• Book Visit Date with Central Office. Enter next visit date on tracking log, VTOC, 
ENDMRSA calendar.  
• Enter new survey data in to VTOC.  File hard copy into subject folder in  locked  
cabinet.  Ask Central Office for file cabinet key.  
• Swabs  to be transported to microbiology laboratory  for processing  
• If CHG compliance swabs were performed, bring back to office for logging and 
shipme nt preparation  
• If adverse event form is completed email information as soon as possible to Central 
Office.  
• Provide signed “Certification of Payment to Anonymous Person – ICTS Irvine” to 
Central Office or sign back in money if visit was not completed with Fiscal Officer . 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
46 
 
 
  
14.  Adverse Event Reporting  
 
Adverse events will be collected at the follow -up visits or when reported by the patient at any 
time. All adverse events should be inputted into the study database and the UCI CO should be 
notified immediately.   The UCI CO will summarize the adverse event on the Adverse Event 
tracking log and will immediately notify the principal investigator of the adverse event.  Adverse 
events reported for patients recruited from Harbor UCLA facilities should reported the Har bor-
UCLA physician co-investigators. Adverse events reported for all other patients should be 
reported to the assigned study physician .  The staff member completing adverse event should let 
the patient know that a study doctor will be following up with the m. 
 
Anticipated mild adverse events will be reported to the IRB on continuing review. All adverse 
events (mild and serious)  will be summarized in the quarterly  DSMB report . Serious Adverse 
Events (SAEs) requiring prompt reporting will be reported within th e required timelines  to the 
IRB and D ata Safety and Monitoring Board.  Any SAEs  that result in a death must be reported to 
the UCI IRB  and DSMB  promptly, within 5  days.  
15. Obtaining Medical Records  
 
Complete m edical records associated with the following w ill be requested from the appropriate 
medical center:  
x The enrollment hospitalization  
x Any subsequent hospitalization  
x Any outpatient visit associated with a ny suspected infection , even if infection was not the 
purpose of the outpatient visit  
 
All subjects wi ll sign a page waiver allowing study personnel to request their medical records 
from any appropriate medical center. Study coordinators will fax, mail, or go in person  to the 
request medical records as soon as the subject notifies them of the hospitalizati on or outpatient  
visit. If study coordinators do not receive the medical records within two week s, they will send a 
repeat request up to 5 times.  If incomplete records are received, another five attempts will be 
made to secure complete data.  
16.  Data Entr y 
 
Data entry will be performed by personnel at UCI and LA BioMed on a secure online database 
developed by Vision Tree Optimal Care (VTOC).  
 
 
 
 
 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
47 
 
 
 Figure 16.1: Vision Tree Optimal Care webpage.  
 
 
All forms must be checked for completeness and accuracy befor e being entered by the data 
management team. Incomplete or inaccurate forms will be flagged and the responsible personnel 
will be contacted to verify answers on the form.  
 
Inaccuracies will be recorded as a means of monitoring the quality of the data repo rted. Data 
quality report s will be issued month ly by the data management team.   
17. Ordering Supplies  
 
Each site will be responsible for ordering their own  office and laboratory  supplies.  
 
The UCI group wil l be responsible for providing intervention toolki ts and  lab coats.  UCI will 
also be responsible for emailing the latest versions of interviews, questionnaires, and other forms 
to the Project CLEAR Team.  
 
The UCI group maintains a detailed inventory tracking log for all study supplies.  Each item has 
an individual tracking sheet.  Anytime a supply or product is taken  from the central  supply area , 
study personnel are responsible for recording the date, initials and number taken on th e 
appropriate inventory sheet. UCI CO is responsible for monitoring inven tory and requesting 
supplies before stock is depleted.  When new stock is received, UCI CO updates the tracking l og 
to reflect the number added.  
 
Decolonization supplies will be kept in a temperature controlled area.  
18.  Enrollment Reports  
 
Enrollment rep orts that show the progress of recruitment are to be created daily and sent to the 
Principle I nvestigator and Senior Project Coordinator Supervisor  each Friday. The report will be 
discussed each Monday at the investigative team call at 11:00 AM (PST). The enrollment report 
contain s information about number of subjects enrolled per week  and per month, progress by 
Project CLEAR MOP Version 1.3 
April 7, 2011  
48 recruiter and recruiting site, number exiting trial and distribution of participants by 
randomization scheme and study arm.  
19. Specimen Delivery and Order Entry
Swab specimens collected from enrolled patie nts must be delivered to the appropriate 
microbiology labor atory within 24 hours of collection. Specimens collected from UCI associated 
facilities must be delivered to UCI Medical Center Microbiology laboratory at the end of each 
day.  Specimens may also be dropped off at the Gottschalk Medical Plaza lab, before 5:00 pm, so 
that the courier service will transport the specimen s to the UCI Medical Center Microbiology 
laboratory that same day. 
The ICTS nurse or study coordinator/recruite r will fill out the Laboratory Requisition sl ip for the 
CLEAR Study Specimens for each patient.  For the Laboratory Requisition slip the ICTS nurse 
or study coordinator/recruiter will be responsible for filling out the Subjec t ID, Collection Date, 
Specimen Collection Origin, Specimen Source and Visit. The ICTS nurse or study 
coordinator/recruite r will also be responsible for filling out his/her name, Date of Collection, 
Number Swabs Taken and Stamp the Study ID number in the four boxes to the left.    
6WXG\VWDII  must notify UCI Central Office of all specimens they have collected for the day.  UCI 
Central Office will record recruiter initials under Visited By, and log the Study ID, Visit 
Location, number of swabs, and Visit Type in the Central Office Lab Count Log.  UCI Central 
Office will send the UCI Medical Center Microbiology laboratory an email (with cc: to UCI lead 
investigator and project supervisor) at the end of the day summarizing the specimens they should 
expect to receive for the day as shown in the table below.   Visited By   (Initials) Study ID Visit Location #  Swabs Visit Type Recruiter Visit number naming convention is R0 (initial recruitment), V1 (study visit 1), V2 (study visit 2), 
V3 (study visit 3), and V4 (study visit 4).  The UCI Medical Center Microbiology laboratory 
sends a reply email verifying that all specimens are accounted for with the correct Study ID and 
paper work. 
Should a problem arise the following is the contact information: 
During regular hours – any issues, call Central Office 855 -363-6772  or call after hours  
numbers if need assistance right away.  
After hours, report of missing swabs etc..  
The project assistant will bring the swabs to the lab. The bag with the specimens will be placed 
by the CLEAR assistant into the bin in the refrigerator in Central Processing.  The bin will be 
marked CLEAR.  
The swabs will be in a plastic bag clearly labeled PROJECT CLEAR containing a lab requisition 
form and CLEAR Specimen Shee t for each patient.  The lab will place the specimen labels that 
Project CLEAR MOP Version 1.3  
April 7 , 2011  
49 
 
 
 go with the corresponding patient on the CLEAR Specimen Sheet received. The Specimen Sheet  
will be kept in the lab and the lab requisition  will be taken to Referral  Services  for billing.  
 
The study location code CLR - will be documented  in the medical record field.  
 
Each swab will be labeled with  the arm of the study (E or D) , a study number (unique for each 
patient) , and an alphabetical designation for randomization strata .  The study -sample i dentifier 
will be entered into the patient name field during the specimen computer order -entry.  In this 
way the specimen ID will appear on all labels.  For example:    
              E1001, NN  
 
This refers to E (education only group) , 1001 is the patient i dentifier , NN means Non -
Hispani c/Non-long term care facilit y. 
 